2025-08-01 2026-07-31 2026-07-31 false 03433979 Kingstown Healthcare Investments Limited 68209Other letting and operating of own or leased real estate iso4217:GBP xbrli:pure 034339792025-08-01 034339792026-07-31 034339792025-08-01 2026-07-31 03433979bus:SmallEntities2025-08-01 2026-07-31 03433979bus:AuditExempt-NoAccountantsReport2025-08-01 2026-07-31 03433979bus:FullAccounts2025-08-01 2026-07-31 03433979core:WithinOneYear2026-07-31 03433979core:AfterOneYear2026-07-31 03433979core:WithinOneYear2025-08-01 2026-07-31 03433979core:AfterOneYear2025-08-01 2026-07-31 03433979core:CurrentFinancialInstruments2026-07-31 03433979core:Non-currentFinancialInstruments2026-07-31 03433979core:CurrentFinancialInstruments2025-08-01 2026-07-31 03433979core:Non-currentFinancialInstruments2025-08-01 2026-07-31 03433979core:LandBuildings2025-08-01 2026-07-31 03433979core:FurnitureFittings2025-08-01 2026-07-31 03433979core:OfficeEquipment2025-08-01 2026-07-31 03433979core:Vehicles2025-08-01 2026-07-31 03433979core:PlantMachinery2025-08-01 2026-07-31 03433979core:OtherPropertyPlantEquipment2025-08-01 2026-07-31 03433979core:LandBuildings2026-07-31 03433979core:PlantMachinery2026-07-31 03433979core:Vehicles2026-07-31 03433979core:FurnitureFittings2026-07-31 03433979core:OfficeEquipment2026-07-31 03433979core:OtherPropertyPlantEquipment2026-07-31 03433979core:Right-of-useAssets2025-08-01 2026-07-31 03433979core:Right-of-useAssets2026-07-31 03433979core:Goodwill2025-08-01 2026-07-31 03433979core:PatentsTrademarksLicencesConcessionsSimilar2025-08-01 2026-07-31 03433979core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-08-01 2026-07-31 03433979core:OtherResidualIntangibleAssets2025-08-01 2026-07-31 03433979core:Goodwill2026-07-31 03433979core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-07-31 03433979core:PatentsTrademarksLicencesConcessionsSimilar2026-07-31 03433979core:OtherResidualIntangibleAssets2026-07-31 03433979dpl:CostSales2025-08-01 2026-07-31 03433979dpl:AdministrativeExpenses2025-08-01 2026-07-31 03433979dpl:DistributionCosts2025-08-01 2026-07-3103433979core:ShareCapital2026-07-31 03433979core:SharePremium2026-07-31 03433979core:RevaluationReserve2026-07-31 03433979core:OtherReservesSubtotal2026-07-31 03433979core:ShareCapitalPreferenceShares2026-07-31 03433979core:CapitalRedemptionReserve2026-07-31 03433979core:OtherCapitalReserve2026-07-31 03433979core:RetainedEarningsAccumulatedLosses2026-07-3103433979core:ShareCapital2025-08-01 2026-07-31 03433979core:SharePremium2025-08-01 2026-07-31 03433979core:RevaluationReserve2025-08-01 2026-07-31 03433979core:OtherReservesSubtotal2025-08-01 2026-07-31 03433979core:RetainedEarningsAccumulatedLosses2025-08-01 2026-07-310343397912025-08-01 2026-07-31 0343397922025-08-01 2026-07-3103433979core:ShareCapital12025-08-01 2026-07-31 03433979core:ShareCapital22025-08-01 2026-07-3103433979core:SharePremium12025-08-01 2026-07-31 03433979core:SharePremium22025-08-01 2026-07-3103433979core:RevaluationReserve12025-08-01 2026-07-31 03433979core:RevaluationReserve22025-08-01 2026-07-3103433979core:RetainedEarningsAccumulatedLosses12025-08-01 2026-07-31 03433979core:RetainedEarningsAccumulatedLosses22025-08-01 2026-07-310343397912025-08-01 2026-07-3103433979core:Non-currentFinancialInstrumentscore:CostValuation2025-08-01 03433979core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:CostValuation2026-07-3103433979core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-08-01 03433979core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-07-31 03433979core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-07-31 03433979core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-07-3103433979core:Non-currentFinancialInstruments2026-07-31 03433979core:Non-currentFinancialInstruments2025-07-31034339792024-08-01 034339792025-07-31 034339792024-08-01 2025-07-31 03433979core:WithinOneYear2025-07-31 03433979core:AfterOneYear2025-07-31 03433979core:CurrentFinancialInstruments2025-07-31 03433979core:Non-currentFinancialInstruments2025-07-31 03433979core:LandBuildings2025-07-31 03433979core:PlantMachinery2025-07-31 03433979core:Vehicles2025-07-31 03433979core:FurnitureFittings2025-07-31 03433979core:OfficeEquipment2025-07-31 03433979core:OtherPropertyPlantEquipment2025-07-31 03433979core:Right-of-useAssets2025-07-31 03433979core:Goodwill2025-07-31 03433979core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-07-31 03433979core:PatentsTrademarksLicencesConcessionsSimilar2025-07-31 03433979core:OtherResidualIntangibleAssets2025-07-31 03433979dpl:AdministrativeExpenses2024-08-01 2025-07-3103433979core:ShareCapital2025-07-31 03433979core:SharePremium2025-07-31 03433979core:RevaluationReserve2025-07-31 03433979core:OtherReservesSubtotal2025-07-31 03433979core:ShareCapitalPreferenceShares2025-07-31 03433979core:CapitalRedemptionReserve2025-07-31 03433979core:OtherCapitalReserve2025-07-31 03433979core:RetainedEarningsAccumulatedLosses2025-07-3103433979core:RetainedEarningsAccumulatedLosses2024-08-01 03433979core:ShareCapital2024-08-01 03433979core:SharePremium2024-08-01 03433979core:RevaluationReserve2024-08-01 03433979core:ShareCapital2024-08-01 2025-07-31 03433979core:SharePremium2024-08-01 2025-07-31 03433979core:RevaluationReserve2024-08-01 2025-07-31 03433979core:OtherReservesSubtotal2024-08-01 2025-07-31 03433979core:RetainedEarningsAccumulatedLosses2024-08-01 2025-07-310343397912024-08-01 2025-07-31 0343397922024-08-01 2025-07-3103433979core:ShareCapital12024-08-01 2025-07-31 03433979core:ShareCapital22024-08-01 2025-07-3103433979core:SharePremium12024-08-01 2025-07-31 03433979core:SharePremium22024-08-01 2025-07-3103433979core:RevaluationReserve12024-08-01 2025-07-31 03433979core:RevaluationReserve22024-08-01 2025-07-3103433979core:RetainedEarningsAccumulatedLosses12024-08-01 2025-07-31 03433979core:RetainedEarningsAccumulatedLosses22024-08-01 2025-07-3103433979bus:Director12025-08-01 2026-07-3103433979bus:PrivateLimitedCompanyLtd2025-08-01 2026-07-31
Kingstown Healthcare Investments Limited
Unaudited Financial Statements
for the year ended 31 July 2026
Company registration number 03433979
(England and Wales)

Company Information

For the year ended 31 July 2026
Director M C Fitch

Company secretary FC Secretarial Services Limited

Registered office 222 Quadrangle Tower
Cambridge Square
London
W2 2PJ

Registered number 03433979

Accountant UHY Hacker Young Fitch
Suite 2.06
Custom House
Custom House Square
Belfast
Northern Ireland
BT1 3ET

Statement of Financial Position

As at 31 July 2026
Notes
2026
2025
£
£
£
£
Fixed assets
Investment property
7,642,922
7,642,922
7,642,922
7,642,922
Current assets
Debtors
242,740
247,160
Cash at bank and in hand
193,892
201,487
436,632
448,647
Creditors
Amounts falling due within one year
5
(320,319)
(302,047)
(320,319)
(302,047)
Net current assets (liabilities)
116,313
146,600
Total assets less current liabilities
7,759,235
7,789,522
Creditors
Amounts falling due after one year
6
(1,641,330)
(1,851,254)
(1,641,330)
(1,851,254)
Provisions for liabilities
7
(542,450)
(541,412)
Net assets (liabilities)
5,575,455
5,396,856
Capital and reserves
Called up share capital
10,000
10,000
Other reserves
3,367,877
3,367,877
Profit and loss account
2,197,578
2,018,979
Total equity
5,575,455
5,396,856

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the director on 23 October 2026 and are signed on its behalf by:

M C Fitch
M C Fitch
Director

Company registration number 03433979

Notes to the Financial Statements

For the year ended 31 July 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.

2.3. Turnover

Turnover represents rental income receivable from the property.

2.4. Foreign currencies

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

2.5. Deferred tax

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

2.6. Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or valuation less depreciation.

2.7. Investment property

Investment property is carried at fair value determined annually and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.

2.8. Financial instruments

Election and recognition

The company has elected to apply the provisions of Section 11 Basic Financial Instruments of FRS 102 to all of its financial instruments.


Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, including debtors, cash at bank and amounts due from related parties, are initially measured at transaction price and subsequently measured at amortised cost where appropriate.


Financial assets are assessed for indicators of impairment at each reporting date. Where there is objective evidence of impairment, any impairment loss is recognised in profit or loss.

Basic financial liabilities

Basic financial liabilities, including creditors, bank borrowings and amounts due to related parties, are initially recognised at transaction price and subsequently measured at amortised cost using the effective interest method where appropriate.

3. Employees

The average number of employees during the year was 1 (2025: 1).

4. Investment property

Valuation
£
At 1 August 2025
7,642,922
At 31 July 2026
7,642,922

The Land and Buildings are an investment property rented to a group company. On 6th October 2020, the company property, Harwood House, was professionally valued by Christie & Co in accordance with the RICS Valuation - Global Standards (the "Red Book"), incorporating the International Valuation Standards ("IVS"), both effective from 31st January 2020. In Christie & Co's opinion, the Market Value of the Freehold Interest in the Property in its existing use and present condition as a fully equipped and operating entity, having regard to its trading potential as at the valuation date is £7,900,000.


The company owns the freehold interest in Harwood House, which is leased to its fellow group undertaking, Harwood House Limited, the operator of the nursing home business.


The directors have considered the value of the nursing home property as a whole and estimate that the combined value of the site at 31 July 2026 was approximately £7,995,888. Included within this amount are leasehold improvements and other leasehold assets with a carrying value of £352,966 recognised in Harwood House Limited.


After excluding these leasehold assets, the directors consider the fair value of the investment property owned by the company to be approximately £7,642,922, which is consistent with the carrying value included in these financial statements.

5. Creditors due within one year

2026
2025
£
£
Bank loans and overdrafts
219,988
207,455
Trade creditors
219
-
Taxation and social security
82,066
73,596
Accruals and deferred income
18,046
20,996
Total
320,319
302,047

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

6. Creditors due after one year

2026
2025
£
£
Bank loans and overdrafts
976,712
1,196,700
Amounts owed to group undertakings
664,618
654,554
Total
1,641,330
1,851,254

Details of security provided: Charges to the Bank (for itself and any relevant company within the Bank group):

1.) A first legal charge over Harwood House.

2.) A first, fixed and floating charge over all assets of the company.

3.) A first, fixed and floating charge over all assets of Harwood House Limited.

4.) A deed of assignment over rental income.

5.) A cross company guarantee of Peterock Limited and Harwood House Limited.

7. Provisions for liabilities

2026
2025
£
£
Deferred tax
542,450
541,412
Total
542,450
541,412

8. Deferred Tax

The deferred tax asset and provision consists of the following deferred tax liabilities/(assets):

2026
2025
£
£
Accelerated capital allowances
542,450
541,412
Net deferred tax liabilities/(assets)
542,450
541,412
Deferred tax liabilities
542,450
541,412
Net deferred tax liabilities/(assets)
542,450
541,412

The values of the deferred tax liabilities/(assets) at the balance sheet date have been calculated using the applicable rate when the asset is expected to be realised.

9. Related party transactions

During the year the company entered into transactions with related parties in the normal course of business on normal commercial terms. The company received rental income, made interest payments, management charges and paid professional and consultancy fees to related parties. These transactions were taken in the normal course of business with outstanding balances repayable on normal commercial terms


Transactions with related parties during the year were as follows:


Fellow group undertakings

Rental income from a fellow group undertaking was £624,720 (2025: £624,720).

Transactions with related parties included management charges totalling £58,350 (2025: £56,650).

Amounts outstanding at the year end and included within debtors were £242,740 (2025: £245,833).


Entities controlled by key management personnel

Transactions with related parties included management charges and interest charges totalling £104,345 (2025: £101,883).

Amounts outstanding at the year end and included within long-term creditors were £664,618 (2025: £654,554).


Other related parties

Purchases from related parties were £6,540 (2025: £6,256).

Amounts outstanding at the year end and included within debtors were £nil (2025: £1,327).

10. Controlling party

Kingstown Healthcare Investments Limited is a wholly owned subsidiary of Peterock Limited. Peterock Limited is registered in England at 222 Quadrangle Tower, Cambridge Square, London, W2 2PJ.


The ultimate controlling party is M C Fitch by virtue of his shareholdings in Peterock Limited